| Literature DB >> 33489905 |
Xiaoli Liu1, Qingfeng Fu1, Xuehai Bian1, Yantao Fu1, Jingwei Xin1, Nan Liang1, Shijie Li1, Yishen Zhao1, Li Fang1, Changlin Li1, Jiao Zhang1, Gianlorenzo Dionigi2, Hui Sun1.
Abstract
The principal issue derived from thyroid cancer is its high propensity to metastasize to the lymph node. Aberrant exprssion of long non-coding RNAs have been extensively reported to be significantly correlated with lymphatic metastasis of thyroid cancer. However, the clinical significance and functional role of lncRNA-MAPK8IP1P2 in lymphatic metastasis of thyroid cancer remain unclear. Here, we reported that MAPK8IP1P2 was downregulated in thyroid cancer tissues with lymphatic metastasis. Upregulating MAPK8IP1P2 inhibited, while silencing MAPK8IP1P2 enhanced anoikis resistance in vitro and lymphatic metastasis of thyroid cancer cells in vivo. Mechanistically, MAPK8IP1P2 activated Hippo signaling by sponging miR-146b-3p to disrupt the inhibitory effect of miR-146b-3p on NF2, RASSF1, and RASSF5 expression, which further inhibited anoikis resistance and lymphatic metastasis in thyroid cancer. Importantly, miR-146b-3p mimics reversed the inhibitory effect of MAPK8IP1P2 overexpression on anoikis resistance of thyroid cancer cells. In conclusion, our findings suggest that MAPK8IP1P2 may serve as a potential biomarker to predict lymphatic metastasis in thyroid cancer, or a potential therapeutic target in lymphatic metastatic thyroid cancer.Entities:
Keywords: Hippo signaling; MAPK8IP1P2; anoikis resistance; lymph node metastasis; thyroid cancer
Year: 2021 PMID: 33489905 PMCID: PMC7817949 DOI: 10.3389/fonc.2020.600927
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244